Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol

Radiology

Volumn 261, Issue 3, 2011, Pages 796-804

  Gahramanov, Seymur ^a   Muldoon, Leslie L ^a   Li, Xin ^b   Neuwelt, Edward A ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FERUMOXYTOL; GADODIAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN BLOOD VOLUME; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLIOMA; HUMAN; HUMAN CELL; LOADING DRUG DOSE; NONHUMAN; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD VOLUME; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; CONTRAST MEDIA; FERUMOXYTOL; GADOLINIUM DTPA; GLIOMA; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; RATS; RATS, NUDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 81555218167     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11103503     Document Type: Article

References (37)

1. Jain RK. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 2005; 19 (4 Suppl 3): 7-16.
2. Wong ET, Brem S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol 2007; 25 (30): 4705-4706. (Pubitemid 350086470)
3. Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Kraemer DF, Neuwelt EA. Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. Neuro Oncol 2009; 11 (2): 142-150.
4. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27 (28): 4733-4740.
5. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009; 252 (1): 182-189.
6. Maeda M, Itoh S, Kimura H, et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993; 189 (1): 233-238. (Pubitemid 23292954)
7. Rollin N, Guyotat J, Streichenberger N, Honnorat J, Tran Minh VA, Cotton F. Clinical relevance of diffusion and perfusion magnetic resonance imaging in assessing intraaxial brain tumors. Neuroradiology 2006; 48 (3): 150-159. (Pubitemid 43380227)
8. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994; 191 (1): 41-51.
9. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999; 211 (3): 791-798. (Pubitemid 29249482)
10. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998; 171 (6): 1479-1486. (Pubitemid 28531609)
11. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004; 25 (2): 214-221. (Pubitemid 38235298)
12. Cao Y, Tsien CI, Nagesh V, et al. Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys 2006; 64 (3): 876-885. (Pubitemid 43183588)
13. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008; 247 (2): 490-498.
14. Oh J, Henry RG, Pirzkall A, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to- N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004; 19 (5): 546-554. (Pubitemid 38619916)
15. Danchaivijitr N, Waldman AD, Tozer DJ, et al. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology 2008; 247 (1): 170-178.
16. Barajas RF Jr, Chang JS, Segal MR, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009; 253 (2): 486-496.
17. Hoefnagels FW, Lagerwaard FJ, Sanchez E, et al. Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. J Neurol 2009; 256 (6): 878-887.
18. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009; 30 (3): 552-558.
19. Gahramanov S, Raslan AM, Muldoon LL, et al. Potential for differentiation of pseudo-progression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011; 79 (2): 514-523.
20. Law M. Advanced imaging techniques in brain tumors. Cancer Imaging 2009; 9 (Spec No A): S4-S9.
21. Muldoon LL, Gahramanov S, Li X, Marshall DJ, Kraemer DF, Neuwelt EA. Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. Neuro Oncol 2011; 13 (1): 51-60.
22. Varallyay CG, Muldoon LL, Gahramanov S, et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab 2009; 29 (4): 853-860.
23. Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008; 249 (2): 601-613.
24. Cha S. Perfusion MR imaging of brain tumors. Top Magn Reson Imaging 2004; 15 (5): 279-289.
25. Heiland S, Benner T, Debus J, Rempp K, Reith W, Sartor K. Simultaneous assessment of cerebral hemodynamics and contrast agent uptake in lesions with disrupted blood-brain barrier. Magn Reson Imaging 1999; 17 (1): 21-27. (Pubitemid 29036101)
26. Uematsu H, Maeda M. Double-echo perfusion-weighted MR imaging: basic concepts and application in brain tumors for the assessment of tumor blood volume and vascular permeability. Eur Radiol 2006; 16 (1): 180-186. (Pubitemid 43103583)
27. Hu LS, Baxter LC, Pinnaduwage DS, et al. Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in post-treatment gliomas. AJNR Am J Neuroradiol 2010; 31 (1): 40-48.
28. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006; 27 (4): 859-867. (Pubitemid 44897737)
29. Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neuro-oncology and central nervous system inflammatory pathologies-a review. J Cereb Blood Flow Metab 2010; 30 (1): 15-35.
30. Amemiya S, Akahane M, Aoki S, et al. Dynamic contrast-enhanced perfusion MR imaging with SPIO: a pilot study. Invest Radiol 2009; 44 (9): 503-508.
31. Neuwelt EA, Várallyay CG, Manninger S, et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 2007; 60 (4): 601-611, discussion 611-612.
32. Neuwelt EA, Hamilton BE, Varallyay CG, et al. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)? Kidney Int 2009; 75 (5): 465-474.
33. Valter MM, Wiestler OD, Pietsche T. Differential control of VEGF synthesis and secretion in human glioma cells by IL-1 and EGF. Int J Dev Neurosci 1999; 17 (5-6): 565-577. (Pubitemid 29421843)
34. Wu YJ, Muldoon LL, Dickey DT, Lewin SJ, Varallyay CG, Neuwelt EA. Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. Neoplasia 2009; 11 (2): 187-195.
35. Ostergaard L, Sorensen AG, Kwong KK, Weisskoff RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. II. Experimental comparison and preliminary results. Magn Reson Med 1996; 36 (5): 726-736. (Pubitemid 26376711)
36. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10 (3): 223-232. (Pubitemid 29463104)
37. Li X, Rooney WD, Várallyay CG, et al. Dynamic contrast-enhanced MRI with extravasating contrast reagent: rat cerebral glioma blood volume determination. J Magn Reson 2010; 206 (2): 190-199.